3 Chronic Therapy, Enzyme and Pharmacy Retail Stocks With a Strong Future Roadmap: Mankind Pharma, Advanced Enzyme Technologies and Medplus Health Services
- October 13, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Mankind Pharma Rs 2,400.00, P/E 47.91. Advanced Enzyme Rs 266.70, P/E 17.28. Medplus Rs 627.60, P/E 36.06. Closing prices of 12 Oct 2026.
Quick Answer
Chronic therapy, enzyme and pharmacy retail stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, Advanced Enzyme in enzymes and probiotics for food, nutrition and pharma and Medplus in a pharmacy retail chain across several states. FY26 revenue growth was 14.8% at Mankind Pharma, 16.5% at Advanced Enzyme and 12.6% at Medplus. P/E stands at 47.91 for Mankind Pharma (industry 37.59), 17.28 for Advanced Enzyme (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Chronic therapy, enzyme and pharmacy retail stocks give investors exposure to medicines, nutrition ingredients and pharmacy stores that patients rely on. Prescription growth, store additions and margins decide how much of that demand turns into profit.
This list covers three chronic therapy, enzyme and pharmacy retail stocks: Mankind Pharma for branded formulations across chronic and acute therapies, Advanced Enzyme Technologies for enzymes and probiotics for food, nutrition and pharma and Medplus Health Services for a pharmacy retail chain across several states. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Chronic Therapy, Enzyme and Pharmacy Retail Stocks?
Chronic therapy, enzyme and pharmacy retail stocks are shares of companies that make medicines and health ingredients or sell them through pharmacy stores. Results depend on prescription growth, store additions and margins, so growth and margins separate the stronger names.
Chronic Therapy, Enzyme and Pharmacy Retail Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three chronic therapy, enzyme and pharmacy retail stocks as of the 12 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Mankind Pharma | 2,400.00 | 99,065 | 47.91 | 37.59 | 11.74% | 0.39 |
| Advanced Enzyme Technologies | 266.70 | 2,967 | 17.28 | 37.59 | 10.34% | 0.02 |
| Medplus Health Services | 627.60 | 7,589 | 36.06 | 66.59 | 11.12% | 0.72 |
Among healthcare stocks, Mankind Pharma trades at a premium to the industry P/E, while Advanced Enzyme and Medplus trade at a discount.
Why Do Chronic Therapy, Enzyme and Pharmacy Retail Stocks Have a Strong Roadmap in India?
Chronic therapy, enzyme and pharmacy retail stocks have a strong roadmap in India because health spending, chronic disease care and growth of organised pharmacies keep lifting demand for these businesses. Three drivers stand out.
- Chronic care: Long-term therapies bring repeat prescriptions.
- Nutrition ingredients: Food and health makers need enzymes and probiotics.
- Organised retail: Pharmacy chains gain share from small stores.
Mankind Pharma: Branded Formulations Anchor the Roadmap
Mankind Pharma’s roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.
Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.
Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.
Advanced Enzyme Technologies: Enzymes and Probiotics Build the Next Leg
Advanced Enzyme’s roadmap rests on enzymes and probiotics for food, nutrition, pharma and animal feed, with a wide industrial customer base supporting revenue.
Revenue grew from Rs 535.80 crore in FY22 to Rs 780.59 crore in FY26, a 45.7% rise, and FY26 revenue was 16.5% higher than FY25. FY26 net profit rose 29.6% to Rs 173.61 crore. Over four years, net profit rose from Rs 123.80 crore in FY22 to Rs 173.61 crore. In Q1 FY27, revenue grew 4.1% to Rs 202.81 crore. Operating margin was 37.06% in FY26.
Debt to equity is 0.02 and return on equity is 10.34%. FY26 operating cash flow was Rs 156.78 crore against capital expenditure of Rs 52.38 crore. Advanced Enzyme paid a dividend of Rs 5.35 per share for FY26, a yield of 2.02%. At a P/E of 17.28 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: The P/E of 17.28 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Medplus Health Services: Pharmacy Retail Stores Anchor the Roadmap
Medplus’ roadmap rests on a pharmacy retail chain with stores across several states, with store expansion supporting revenue.
Revenue grew from Rs 3,810.64 crore in FY22 to Rs 6,963.79 crore in FY26, an 82.7% rise, and FY26 revenue was 12.6% higher than FY25. FY26 net profit rose 46.2% to Rs 219.61 crore. Over four years, net profit rose from Rs 94.72 crore in FY22 to Rs 219.61 crore. In Q1 FY27, revenue grew 21.9% to Rs 1,899.43 crore. Operating margin was 9.85% in FY26.
Debt to equity is 0.72 and return on equity is 11.12%. FY26 operating cash flow was Rs 495.58 crore against capital expenditure of Rs 123.03 crore. At a P/E of 36.06 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Net profit margin is only 3.2%, so small cost changes move earnings.
Best Chronic Therapy, Enzyme and Pharmacy Retail Stocks in India: Mankind Pharma vs Advanced Enzyme vs Medplus on Key Financials
Among the best chronic therapy, enzyme and pharmacy retail stocks in India, Mankind Pharma leads on return on equity; Advanced Enzyme leads on FY26 revenue growth and FY26 operating margin; Medplus leads on Q1 FY27 revenue growth. The table puts the numbers side by side.
| Metric | Mankind Pharma | Advanced Enzyme | Medplus |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 14,636.43 | 780.59 | 6,963.79 |
| FY26 revenue growth | 14.8% | 16.5% | 12.6% |
| FY26 net profit (Rs Cr) | 1,938.10 | 173.61 | 219.61 |
| FY26 operating profit margin | 27.06% | 37.06% | 9.85% |
| Q1 FY27 revenue growth (YoY) | 11.7% | 4.1% | 21.9% |
| Return on equity | 11.74% | 10.34% | 11.12% |
| P/E ratio | 47.91 | 17.28 | 36.06 |
| Debt to equity | 0.39 | 0.02 | 0.72 |
| Dividend yield | 0.04% | 2.02% | 0.00% |
| FY26 operating cash flow (Rs Cr) | 3,121.29 | 156.78 | 495.58 |
Healthcare earnings follow prescription growth, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Chronic Therapy, Enzyme and Pharmacy Retail Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen chronic therapy, enzyme and pharmacy retail stocks and shortlist chronic therapy, enzyme and pharmacy retail stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these chronic therapy, enzyme and pharmacy retail stocks
Risks to Consider Before Investing in Chronic Therapy, Enzyme and Pharmacy Retail Stocks
- Pricing rules: Price controls can affect margins.
- Competition: Online and offline rivals can pressure sales.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Mankind Pharma, Advanced Enzyme and Medplus live.
Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.
Comparing a quarter with the same quarter of the previous year gives a cleaner reading than comparing it with the preceding quarter, since seasonal patterns affect many businesses in India.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover branded formulations, enzymes and probiotics, and pharmacy stores. Mankind Pharma leads on return on equity; Advanced Enzyme leads on FY26 revenue growth and FY26 operating margin; Medplus leads on Q1 FY27 revenue growth.
Across chronic therapy, enzyme and pharmacy retail stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the chronic therapy, enzyme and pharmacy retail stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Chronic Therapy, Enzyme and Pharmacy Retail Stocks
Which are the best chronic therapy, enzyme and pharmacy retail stocks in India with a strong roadmap?
Ans. Mankind Pharma, Advanced Enzyme Technologies and Medplus Health Services stand out for their roadmaps in branded formulations, enzymes and probiotics, and pharmacy stores. FY26 revenue growth was 14.8% at Mankind Pharma, 16.5% at Advanced Enzyme and 12.6% at Medplus, and return on equity ranges from 10.34% to 11.74%.
Is Mankind Pharma a good stock to buy now?
Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Mankind Pharma, Advanced Enzyme and Medplus?
Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 17.28 for Advanced Enzyme (industry 37.59) and 36.06 for Medplus (industry 66.59). Only Mankind Pharma trades at or above the industry multiple.
Which of these chronic therapy, enzyme and pharmacy retail stocks has the highest return on equity?
Ans. Mankind Pharma has the highest return on equity at 11.74%, followed by Medplus Health Services at 11.12% and Advanced Enzyme Technologies at 10.34%.
What are the risks of investing in chronic therapy, enzyme and pharmacy retail stocks?
Ans. The main risks are pricing rules, competition and quarterly trends. Price controls can affect margins.
How did Mankind Pharma, Advanced Enzyme and Medplus perform in Q1 FY27?
Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Advanced Enzyme Technologies reported revenue of Rs 202.81 crore, up 4.1% year on year. Medplus Health Services reported revenue of Rs 1,899.43 crore, up 21.9% year on year.
Do chronic therapy, enzyme and pharmacy retail stocks pay dividends?
Ans. Mankind Pharma and Advanced Enzyme pay dividends. The dividend yield is 0.04% for Mankind Pharma and 2.02% for Advanced Enzyme, based on dividends declared for FY26.
How can I invest in chronic therapy, enzyme and pharmacy retail stocks in India?
Ans. You can buy chronic therapy, enzyme and pharmacy retail stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
